期刊文献+

AML/TMDS与MDS-AML的对比研究 被引量:1

Comparative Study on AML/TMDS and MDS-AML
下载PDF
导出
摘要 目的 :分析三系病态造血的急性髓系白血病 (AML/TMDS)与骨髓增生异常综合征演变为急性髓系白血病 (MDS AML)的差异。方法 :采用常规形态学和细胞化学染色方法观察患者外周血和骨髓细胞。结果 :AML/TMDS患者血小板计数和外周原始细胞百分率高于MDS AML(P <0 0 5 ,P <0 0 1) ;小巨核细胞和Pseudo pelger异常明显低于MDS AML(P <0 0 5 ,P <0 0 1) ,2组病例MPO染色阳性率基本一致 ,但AML/TMDS患者MPO积分显著高于MDS AML(P <0 0 1)。AML/TMDS患者多核原始红细胞明显低于MDS AML(P <0 0 5 ) ;AML/TMDS与MDS AML患者巨大血小板分别为 2 3 1%和 86 7%。结论 :AML/TMDS与MDS AML白血病克隆不同 ,正确诊断对确定方案。 Objective To investigate the distinction between AML/TMDS and MDS AML.Methods Morpholism and cell chemical staining were used to study the periferal blood cells and marrow cells.Results The percentages of platelet and peripheral primitive cells were both higher than those in MDS AML( P <0 05, P <0 01).And percentages of macronuclear cells and Pseudo pelger were lower than those in MDS AML( P <0 05, P <0 01).The positive rates of MPO stain in two cases were roughly concordant,but the MPO score in patients with AML/TMDS was absolutely higher than that of MDS AML( P <0 01).And they had lower number of multinuclear primitive erythrocytes than MDS AML( P <0 05).Percentages of giant platelet in two cases were 23 1% and 86 7% respectively.Conclusions AML/TMDS and MDS AML originate from different leukemia clone.Correct diagnosis is important to determine the treatment scheme,to judge curative effect and prognosis. China J Cancer Prev Treat,2003,10(3):292-293
出处 《肿瘤防治杂志》 2003年第3期292-293,共2页 China Journal of Cancer Prevention and Treatment
关键词 白血病 粒细胞 急性 三系病态造血 leukemia,myelocytic,acute TMDS
  • 相关文献

参考文献1

二级参考文献28

  • 1Third MIC Cooperative Study Group. Cancer Genet Cytogenet, 1988,32:1
  • 2Sole F, Espinet B,Sanz GF, et al. Br J Haematol, 2000,108: 346
  • 3Morel P, Hebbar M, Lai JL, et al. Leukemia, 1993,7:1315
  • 4Toyama K, Ohyashiki K, Yoshida Y, et al. Leukemia, 1993,7: 499
  • 5Fernandez TS, Ornellas MH, de Carvalho LO, et al. Leuk Res, 2000,24: 830
  • 6Greenberg P, Cox C, Leubeau MM, et al. Blood, 1997,89: 2047
  • 7Greenberg P. Leuk Res, 1998,22:S3
  • 8Lee JJ,Kim HJ ,Chung IJ,et al. Leuk Res,1999,23:425
  • 9Oriani A,Annaloro C,Soligo D,et al. Br J Haematol,1996,92:360
  • 10Sullivan SA,Marsden KA, Lowenthal RM, et al. Am J Hematol, 1992,39:96

共引文献1

同被引文献5

  • 1[2]Brito-Babapulle F,Catovsky D,Galton DA.Clinical and labora tory features of de novo acute myeloid leukaemia with trilineage myelodysplasia[J].Br J Haematol,1987,66(4):445-450.
  • 2[3]Kuriyama K,Tomonaga M,Matsuo T,et al.Poor response to intensive chemotherapy in de novo acute myeloid leukaemia with trilineage myelodysplasia.Japan Adult Leukaemia Study Group (JALSG)[J].Br J Haematol,1994,86(4):767-773.
  • 3[6]Tsukaguchi M,Furukawa Y,Shibano M,et al.Five cases of denovo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)][J].Gan To Kagaku Ryoho,2004,31(7):1119-1123.
  • 4[7]Maeda N,Satake S,Okada Y,et al.All-trans retinoic acid combined with low-dose cytosine arabinoside treatment for acute myelogenous leukemia with trilineage myelodysplasia-a case report[J].Gan To Kagaku Ryoho,2001,28(3):407-410.
  • 5童向民,金洁,宋菊贞,陈志妹.急性髓细胞白血病伴三系病态造血的临床意义[J].中华检验医学杂志,2003,26(10):620-621. 被引量:2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部